Liraglutide, a glucagon-like peptide 1 (GLP-1) analog used to treat type 2 diabetes, increases the postprandial insulin level in a glucose-dependent manner and reduces glucagon secretion, leading to improved postprandial glucose metabolism. Here, GCG is linked to type 2 diabetes mellitus.